Free Trial

Baxter International (BAX) Stock Forecast & Price Target

Baxter International logo
$33.21 +0.22 (+0.67%)
(As of 11/22/2024 ET)

Baxter International - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
7
Buy
3

Based on 11 Wall Street analysts who have issued ratings for Baxter International in the last 12 months, the stock has a consensus rating of "Hold." Out of the 11 analysts, 1 has given a sell rating, 7 have given a hold rating, and 3 have given a buy rating for BAX.

Consensus Price Target

$40.91
23.18% Upside
According to the 11 analysts' twelve-month price targets for Baxter International, the average price target is $40.91. The highest price target for BAX is $54.00, while the lowest price target for BAX is $30.00. The average price target represents a forecasted upside of 23.18% from the current price of $33.21.
Get the Latest News and Ratings for BAX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Baxter International and its competitors.

Sign Up

BAX Analyst Ratings Over Time

TypeCurrent Forecast
11/24/23 to 11/23/24
1 Month Ago
10/25/23 to 10/24/24
3 Months Ago
8/26/23 to 8/25/24
1 Year Ago
11/24/22 to 11/24/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
4 Buy rating(s)
Hold
7 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$40.91$42.00$41.73$47.25
Forecasted Upside23.18% Upside14.38% Upside11.15% Upside31.18% Upside
Consensus Rating
Hold
Hold
Hold
Hold

BAX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BAX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Baxter International Stock vs. The Competition

TypeBaxter InternationalMedical CompaniesS&P 500
Consensus Rating Score
2.18
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside23.18% Upside27,098.21% Upside7.66% Upside
News Sentiment Rating
Neutral News

See Recent BAX News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/11/2024Stifel Nicolaus
4 of 5 stars
 Lower TargetBuy ➝ Buy$46.00 ➝ $38.00+11.73%
10/1/2024Citigroup
3 of 5 stars
 Boost TargetNeutral ➝ Neutral$38.00 ➝ $40.00+8.40%
8/8/2024The Goldman Sachs Group
2 of 5 stars
 Boost TargetNeutral ➝ Neutral$36.00 ➝ $40.00+8.20%
8/7/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$44.00 ➝ $42.00+13.61%
8/7/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$44.00 ➝ $40.00+6.84%
7/15/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeEqual Weight ➝ Underweight$39.00 ➝ $30.00-15.06%
7/2/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$46.00 ➝ $45.00+36.12%
5/10/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$40.00+11.27%
3/5/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$42.00 ➝ $45.00+2.93%
2/12/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$52.00 ➝ $54.00+35.71%
2/6/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$40.00 ➝ $36.00-8.28%
10/24/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$35.00 ➝ $50.00+52.72%
7/31/2023KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$53.00 ➝ $51.00+8.49%
5/30/2023888
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingAssumes
2/10/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$70.00 ➝ $45.00+12.11%
1/5/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:45 PM ET.


Should I Buy Baxter International Stock? BAX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, November 21, 2024. Please send any questions or comments about these Baxter International pros and cons to contact@marketbeat.com.

Baxter International
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Baxter International Inc.:

  • Baxter International Inc. was recently upgraded from a "hold" rating to a "buy" rating, indicating positive sentiment from analysts and potential for stock appreciation.
  • The stock is currently trading at $36.59, which is relatively low compared to its one-year high of $44.01, suggesting a potential upside for investors looking to buy at a lower price.
  • Institutional investors own 90.19% of Baxter International Inc.'s stock, reflecting strong confidence from large financial entities in the company's future performance.
  • The company reported a net margin of 16.51% and a return on equity of 18.06%, indicating efficient management and profitability, which are attractive traits for investors.
  • Recent quarterly revenue growth of 2.8% compared to the same quarter last year shows that Baxter International Inc. is maintaining a positive growth trajectory in a competitive market.

Baxter International
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Baxter International Inc. for these reasons:

  • Short interest in Baxter International Inc. has increased by 6.3% recently, indicating that more investors are betting against the stock, which could signal potential concerns about its future performance.
  • Several analysts have recently cut their price targets for the stock, with some lowering it from $44.00 to $40.00, suggesting a lack of confidence in significant price appreciation in the near term.
  • The company has a debt-to-equity ratio of 1.35, which indicates a higher level of debt compared to equity. This could pose risks if the company faces financial difficulties or rising interest rates.
  • Despite a recent upgrade, the average rating remains a "Hold," which may suggest that many analysts are cautious about the stock's potential for significant growth.
  • The stock has a relatively low price-to-earnings ratio of 7.04, which could indicate that the market has lower expectations for future earnings growth compared to other companies in the sector.

BAX Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Baxter International is $40.91, with a high forecast of $54.00 and a low forecast of $30.00.

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last year. There is currently 1 sell rating, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BAX, but not buy additional shares or sell existing shares.

According to analysts, Baxter International's stock has a predicted upside of 23.18% based on their 12-month stock forecasts.

Baxter International has been rated by research analysts at Citigroup, and Stifel Nicolaus in the past 90 days.

Analysts like Baxter International less than other "medical" companies. The consensus rating for Baxter International is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BAX compares to other companies.


This page (NYSE:BAX) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners